Colquhoun B P, Singh R, Miller B J, DeCoteau W E
Can J Surg. 1980 Sep;23(5):487-8.
Actinomycosis is rare and responds well to antibiotic therapy. The causative organism, Actinomyces israelii which is now considered to be a bacterium, has long been suspected of exerting an immunosuppressive effect. The authors provide further evidence of this in their study of three patients with actinomycosis and four healthy control subjects. Skin reactivity to various standard antigens was depressed in all seven patients. Peripheral lymphocytes from the patients and the control subjects were isolated. A. israelii was added to the cell cultures following challenge with several standard mitogens. Blast transformation in response to phytohemagglutinin was inhibited by A. israelii in all seven subjects, but was preserved in response to concanavalin A and pokeweed mitogen. A. israelii appears capable of inhibiting the subset of human peripheral lymphocytes responsive to phytohemagglutinin stimulation in vitro.
放线菌病较为罕见，对抗生素治疗反应良好。致病微生物以色列放线菌现被认为是一种细菌，长期以来一直被怀疑具有免疫抑制作用。作者在对三名放线菌病患者和四名健康对照者的研究中提供了这方面的进一步证据。所有七名患者对各种标准抗原的皮肤反应性均降低。分离出患者和对照者的外周淋巴细胞。在用几种标准有丝分裂原刺激后，将以色列放线菌添加到细胞培养物中。在所有七名受试者中，以色列放线菌均抑制了对植物血凝素的 blast 转化，但对刀豆球蛋白 A 和商陆有丝分裂原的反应则保持不变。以色列放线菌似乎能够在体外抑制对植物血凝素刺激有反应的人类外周淋巴细胞亚群。
